# Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

> **NCT01788007** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 443 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Imiquimod Topical Cream 3.75%
- **DRUG:** Zyclara® (imiquimod) Topical Cream 3.75%
- **DRUG:** Vehicle Topical Cream

## Key facts

- **NCT ID:** NCT01788007
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-12
- **Target enrollment:** 443 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788007, "Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01788007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*